This is a group of five related macular conditions caused by mistakes or mutations in a gene called BEST1.
So far around 300 different mistakes have been identified, causing one of five bestrophinopathies:
- Best vitelliform macular dystrophy (BVMD or “Best disease”)
- Adult vitelliform macular dystrophy (AVMD)
- Autosomal recessive bestrophinopathy (ARB)
- Autosomal dominant vitreoretinochoroidopathy (ADVIRC)
- Retinitis pigmentosa (RP).
Each of these causes a different pattern of damage to the retina, although all except ADVIRC mostly affect the macula.
Each is inherited in a different way – some dominantly (so that carrying even one copy of the gene from one parent is enough to develop the condition) and some recessively (so people only develop symptoms if both their parents have passed on the gene).
In healthy people, the BEST1 gene provides instructions for making a protein called bestrophin-1. This protein is found in a thin layer of cells at the back of the eye called the retinal pigment epithelium (RPE), which supports and nourishes the retina. Bestrophin-1 acts as a funnel to allow chloride ions in and out of RPE cells, to keep them and the retina working properly.
If your copy of BEST1 has a spelling mistake in it, the protein “funnels” it creates don’t work as they should, so the RPE cells are damaged. Without RPE support, retinal cells start to die too, causing blurring, distortion and loss of central vision. Symptoms can affect people at different ages and two people with the same bestrophinopathy may have very different levels of sight loss. Some may never have any symptoms at all.
There is currently no treatment for the root cause of these conditions. Treatment can only be given for new blood vessel growth, as in wet age-related macular degeneration, and this would involve anti-VEGF injections.
At the moment we can’t tell from looking at someone’s genetic code how severely they will be affected, or at what age, but research is continuing to understand more about how each different mistake causes sight loss.
A team in the USA is using gene therapy to “add in” a healthy version of BEST1 to dogs with a related condition. A project funded by the Macular Society and led by Dr Amanda-Jayne Carr is working on a treatment for the dominant version, using gene editing to remove the toxic version of BEST1.
For information about living with an inherited macular dystrophy, call the Helpline on 0300 3030 111 or email email@example.com